(Q37610139)

21 August 2017

1 reference

title

A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours (English)

1 reference

21 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Dominik Wolf

1

1 reference

21 August 2017

Holger Rumpold

series ordinal

2

1 reference

21 August 2017

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

32

1 reference

21 August 2017

11

1 reference

21 August 2017

1001-1015

1 reference

https://scigraph.springernature.com/pub.10.2165/11314600-000000000-00000

21 August 2017

0 references

cites work

Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure

1 reference

12 December 2020

Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

1 reference

12 December 2020

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

12 December 2020

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

12 December 2020

Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy

1 reference

12 December 2020

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

1 reference

12 December 2020

Imatinib in pregnancy.

1 reference

12 December 2020

Targeted cancer therapy

1 reference

12 December 2020

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia

1 reference

12 December 2020

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).

1 reference

12 December 2020

Long-term imatinib therapy promotes bone formation in CML patients

1 reference

12 December 2020

Oncogenic kinase signalling

1 reference

12 December 2020

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

12 December 2020

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

1 reference

12 December 2020

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

12 December 2020

Biology of gastrointestinal stromal tumors.

1 reference

12 December 2020

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors

1 reference

12 December 2020

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

12 December 2020

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

12 December 2020

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

12 December 2020

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk

1 reference

12 December 2020

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

1 reference

12 December 2020

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

12 December 2020

Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature

1 reference

12 December 2020

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

1 reference

12 December 2020

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

1 reference

12 December 2020

Pregnancy on imatinib: fatal outcome with meningocele

1 reference

12 December 2020

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

12 December 2020

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

12 December 2020

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

12 December 2020

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

1 reference

12 December 2020

Congestive heart failure is a rare event in patients receiving imatinib therapy

1 reference

12 December 2020

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

1 reference

12 December 2020

Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

12 December 2020

Gastrointestinal stromal tumors: from a surgical to a molecular approach.

1 reference

12 December 2020

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

12 December 2020

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

1 reference

12 December 2020

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

1 reference

12 December 2020

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

12 December 2020

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

1 reference

12 December 2020

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

12 December 2020

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

12 December 2020

10.2165/11314600-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1035706167

0 references

Fatcat ID

release_k7hmn6vd5vecbjxfbvyksjphfm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k7hmn6vd5vecbjxfbvyksjphfm

24 November 2022

mapped directly with Wikidata item

1 reference